Taysha Gene Therapies, Inc. Depreciation
Taysha Gene Therapies, Inc. (TSHA) reported Depreciation of $400.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-11
- Taysha Gene Therapies, Inc. depreciation for the quarter ending 2026-06-30 was $400.00K, a 33.33% increase year-over-year.
- Taysha Gene Therapies, Inc. depreciation for the quarter ending 2026-03-31 was $295.00K, a 4.24% increase year-over-year.
- Taysha Gene Therapies, Inc. depreciation for the quarter ending 2025-12-31 was $299.00K, a 1.64% decline year-over-year.
- Taysha Gene Therapies, Inc. depreciation for the quarter ending 2025-09-30 was $200.00K, a 33.33% decline year-over-year.
- Taysha Gene Therapies, Inc. depreciation for fiscal 2025 was $1.15M, a 8.03% decline from fiscal 2024.
- Taysha Gene Therapies, Inc. depreciation for fiscal 2024 was $1.25M, a 9.19% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. depreciation for fiscal 2023 was $1.37M, a 16.98% increase from fiscal 2022.
- Taysha Gene Therapies, Inc. depreciation for fiscal 2022 was $1.17M, a 138.21% increase from fiscal 2021.
| Period end | Depreciation 0 month | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-11 | $586.00K 10-Q · filed 2026-08-11 | $994.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.19M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $295.00K 10-Q · filed 2026-05-06 | $594.00K derived: sum of 2 quarters · filed 2026-05-06 | $794.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.09M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $499.00K derived: sum of 2 quarters · filed 2026-03-19 | $799.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.15M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-04 | $500.00K derived: sum of 2 quarters · filed 2026-08-11 | $846.00K 10-Q · filed 2025-11-04 | $1.09M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-11 | $560.00K 10-Q · filed 2026-08-11 | $887.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.19M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $283.00K 10-Q · filed 2026-05-06 | $587.00K derived: sum of 2 quarters · filed 2026-05-06 | $887.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.19M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $604.00K derived: sum of 2 quarters · filed 2026-03-19 | $904.00K derived: sum of 3 quarters · filed 2026-03-19 | $1.25M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-04 | $600.00K derived: sum of 2 quarters · filed 2025-11-04 | $941.00K 10-Q · filed 2025-11-04 | $1.29M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-12 | $647.00K 10-Q · filed 2025-08-12 | $991.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.29M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $325.00K 10-Q · filed 2025-05-15 | $691.00K derived: sum of 2 quarters · filed 2025-05-15 | $991.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.39M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $666.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.07M derived: sum of 3 quarters · filed 2025-02-26 | $1.37M 10-K · filed 2025-02-26 | ||||
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-13 | $700.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.00M 10-Q · filed 2024-11-13 | $1.39M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-12 | $674.00K 10-Q · filed 2024-08-12 | $1.09M derived: sum of 3 quarters · filed 2024-08-12 | $1.39M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $331.00K 10-Q · filed 2024-05-14 | $693.00K derived: sum of 2 quarters · filed 2024-05-14 | $993.00K derived: sum of 3 quarters · filed 2024-05-14 | $1.29M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $362.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $662.00K derived: sum of 2 quarters · filed 2024-03-19 | $962.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.17M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-14 | $600.00K derived: sum of 2 quarters · filed 2023-11-14 | $810.00K 10-Q · filed 2023-11-14 | $808.00K 10-Q · filed 2022-11-08 | $1.07M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-14 | $533.00K 10-Q · filed 2023-08-14 | $531.00K 10-Q · filed 2022-08-11 | $769.00K derived: sum of 3 quarters · filed 2023-08-14 | $969.00K derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $260.00K 10-Q · filed 2023-05-11 | $257.00K 10-Q · filed 2022-05-16 | $469.00K derived: sum of 2 quarters · filed 2023-05-11 | $669.00K derived: sum of 3 quarters · filed 2023-05-11 | $754.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $409.00K derived: sum of 2 quarters · filed 2023-03-28 | $494.00K derived: sum of 3 quarters · filed 2023-03-28 | $492.00K 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | $200.00K 10-Q · filed 2022-11-08 | $166.00K 10-Q · filed 2021-11-10 | $285.00K derived: sum of 2 quarters · filed 2022-11-08 | $283.00K 10-Q · filed 2022-11-08 | $323.00K derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $85.00K 10-Q · filed 2021-08-16 | $117.00K 10-Q · filed 2022-08-11 | $123.00K derived: sum of 3 quarters · filed 2022-05-16 | $126.00K derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2021-03-31 | $32.00K 10-Q · filed 2022-05-16 | $38.00K derived: sum of 2 quarters · filed 2022-05-16 | $41.00K derived: sum of 3 quarters · filed 2022-05-16 | $41.00K derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $9.00K derived: sum of 2 quarters · filed 2022-03-31 | $9.00K derived: sum of 3 quarters · filed 2022-03-31 | $9.00K 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $3.00K derived: sum of 2 quarters · filed 2021-11-10 | $3.00K 10-Q · filed 2021-11-10 | $3.00K derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | $0.00 derived: sum of 3 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | ||||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 | |||||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |